This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Brian W. Blakley, MD, PhD; Anil K. Gupta; Steven F. Myers, PhD; Sabina Schwan, MA

Arch Otolaryngol Head Neck Surg. 1994;120(5):541-546.

Abstract
Objective
To determine whether abnormalities in routine blood tests were associated with increased susceptibility to hearing loss induced by cisplatin chemotherapy.

Design
Cohort study of patients with head and neck cancer receiving cisplatin chemotherapy who underwent audiometric testing.

Setting
A large, university-based hospital; part of a larger study regarding rehabilitation of patients with cancer.

Patients
Forty-two patients with head and neck cancer who agreed to participate underwent at least three serial treatments with high-dose cisplatin therapy. Routine blood tests and audiometric testing were performed before each course of chemotherapy. One hundred eighty audiograms were performed.

Outcome Measures
A deterioration of auditory threshold of 15 dB or more at one frequency or of 10 dB or more at three or more frequencies was considered a significant loss. Only frequencies at and below 4000 Hz were considered.

Results
Multiple analysis of variance results indicated that decreased serum albumin level, hemoglobin level, red blood cell count, and hematocrit were associated with an increased likelihood of significant hearing loss during chemotherapy.

Conclusions
Patients in poor general medical condition with low levels of red blood cells or serum proteins are at increased risk for development of hearing loss from cisplatin chemotherapy. We recommend that hearing be tested before chemotherapy begins and after the first course of cisplatin. If there is no significant hearing loss at or below 4000 Hz at that time, then subsequent audiometric testing is required only if symptoms of hearing loss develop.

(Arch Otolaryngol Head Neck Surg. 1994;120:541-546)

Author Affiliations
From the Departments of Otolaryngology (Drs Blakley and Myers) and Audiology (Ms Schwan), Wayne State University (Mr Gupta), Detroit, Mich.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer
Strumberg et al.
Ann Oncol 2002;13:229-236.
ABSTRACT | FULL TEXT  

Ototoxic Effects of Supradose Cisplatin With Sodium Thiosulfate Neutralization in Patients With Head and Neck Cancer
Madasu et al.
Arch Otolaryngol Head Neck Surg 1997;123:978-981.
ABSTRACT  

A Sensitive Animal Model to Assess Acute and Chronic Ototoxic Effects
Lautermann and Schacht
Arch Otolaryngol Head Neck Surg 1996;122:837-840.
ABSTRACT